Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm

PHASE2CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Fibrillation, Atrial
Interventions
DRUG

fondaparinux

Comparison of different drugs

DRUG

unfractionated heparin

Comparison of different drugs

DRUG

Vitamin-K-Antagonist

Comparison of different drugs

Trial Locations (34)

10249

GSK Investigational Site, Berlin

10405

GSK Investigational Site, Berlin

13353

GSK Investigational Site, Berlin

14467

GSK Investigational Site, Potsdam

19230

GSK Investigational Site, Hagenow

29609

GSK Investigational Site, Brest

31059

GSK Investigational Site, Toulouse

31076

GSK Investigational Site, Toulouse

33604

GSK Investigational Site, Pessac

GSK Investigational Site, Bielefeld

34121

GSK Investigational Site, Kassel

34125

GSK Investigational Site, Kassel

34295

GSK Investigational Site, Montpellier

35033

GSK Investigational Site, Rennes

39120

GSK Investigational Site, Magdeburg

46483

GSK Investigational Site, Wesel

47259

GSK Investigational Site, Duisburg-Huckingen

53115

GSK Investigational Site, Bonn

53127

GSK Investigational Site, Bonn

59423

GSK Investigational Site, Unna

60488

GSK Investigational Site, Frankfurt am Main

63739

GSK Investigational Site, Aschaffenburg

64046

GSK Investigational Site, Pau

75571

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

78740

GSK Investigational Site, Évecquemont

79106

GSK Investigational Site, Freiburg im Breisgau

81000

GSK Investigational Site, Albi

83646

GSK Investigational Site, Bad Tölz

84359

GSK Investigational Site, Simbach A. Inn

86021

GSK Investigational Site, Poitiers

92166

GSK Investigational Site, Antony

94000

GSK Investigational Site, Créteil

01796

GSK Investigational Site, Pirna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY